Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s):  CSCI

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.


TSX:CSCI - Post by User

Comment by prophetoffactzon Nov 21, 2024 1:04pm
54 Views
Post# 36324142

RE:RE:Email Response from Gilles Gagnon on March 12, 2024

RE:RE:Email Response from Gilles Gagnon on March 12, 2024
Stinzo wrote:

I dont know Oats, seems very arrogant to me especially with no track record and no positive momentum for years, 10+ years that is. 

we are unfortunately stuck until something gives I guess. 




Gilles actually knows the cards the company is holding better than anyone. If he's convinces that can be a great sign. We've never seen the data for the pill or the discussions with potential partners for PGX. With a potential proof of principle through safety/tolerability and preliminary efficacy in 2025 from the Phase I/IIa clinical trial and PGX scale-up to the decision point for mass industrialization of PGX only time will tell if Gilles is right. It's just the nature of the situation that the cards are kept close to the vest at this time. Timelines are long. That's life. The recent director suggests promise and the new President and CEO will add more clarity before key events. How credible will the new person be at this key time for the company.
<< Previous
Bullboard Posts
Next >>